Related Experiment Video

Updated: Dec 10, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

744

COVİD-19 infection in a membranous nephropathy patient treated with rituximab

Omer Celal Elcioglu1, Ayse Serra Artan2, Safak Mirioglu2

  • 1Department of Nephrology, Bezmialem Vakif University School of Medicine, Fatih, 34093, Istanbul, Turkey. oelcioglu@bezmialem.edu.tr.

CEN Case Reports
|September 5, 2020
PubMed

Insights

Managing patients with chronic conditions like membranous nephropathy during the COVID-19 pandemic presents challenges. This case report details a patient with nephrotic syndrome treated with rituximab during recent COVID-19 infection.

Area of Science:

  • Nephrology
  • Immunology
  • Infectious Diseases

Background:

  • The COVID-19 pandemic necessitates adaptations in healthcare delivery for chronic disease management.
  • Patients requiring immunosuppressive therapy pose unique challenges for ongoing treatment and monitoring.

Observation:

  • A patient diagnosed with nephrotic syndrome secondary to membranous nephropathy was recently administered rituximab.
  • This patient also had a concurrent diagnosis of COVID-19.

Findings:

  • The report focuses on the clinical course and management of this specific patient case.
  • It highlights the complexities of treating autoimmune kidney diseases with immunosuppressants during a viral pandemic.

Implications:

  • This case contributes to understanding the management of immunosuppressed patients with autoimmune conditions during COVID-19.
  • It underscores the importance of individualized treatment strategies in nephrology during global health crises.

Keywords:
COVID-19CoronavirusImmunosuppressionMembranous nephropathyRituximab

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
95
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
337